Daily Journal Staff Writer
Latham & Watkins LLP is representing biopharmaceutical company ChemoCentryx Inc. and Davis Polk & Wardwell LLP the lead underwriters in the Mountain View-based company's offering of $60 million of common stock, announced Monday.
In a filing to the Securities and Exchange Commission, ChemoCentryx said it would use the proceeds for funding of drug candidate development, working capital an...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In